Levetiracetam (LVT) is a relatively novel antiepileptic drug (AED) known to act through binding with the synaptic vesicular 2A (SV2A) protein, thus modulating the presynaptic neurotransmitter release. The tryptophan metabolite quinolinic acid (QUIN) acts as an excitotoxin when its brain concentrations reach toxic levels under pathological conditions. Since increased neuronal excitability induced by QUIN recruits degenerative events in the brain, and novel AED is also expected to exert neuroprotective effects in their pharmacological profiles, in this work the effect of LVT (54 mg/kg, i.p., administered for seven consecutive days) was tested as a pretreatment against the toxicity evoked by the bilateral intrastriatal injection of QUIN (60 nmol/μl) to adult rats. QUIN increased the striatal levels of peroxidized lipids and carbonylated proteins as indexes of oxidative damage 24 h after its infusion. In addition, in synaptosomal fractions isolated from QUIN-lesioned rats 24 h after the toxin infusion, γ-aminobutyric acid (GABA) release was decreased, whereas glutamate (Glu) release was increased. QUIN also decreased motor activity and augmented the rate of cell damage at 7 days post-lesion. All these alterations were significantly prevented by pretreatment of rats with LVT. The results of this study show a neuroprotective role and antioxidant action of LVT against the brain damage induced by excitotoxic events.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Abdel-Wahab BA, Shaikh IA, Khateeb MM, Habeeb SM (2015) Omega 3 polyunsaturated fatty acids enhance the protective effect of levetiracetam against seizures, cognitive impairment and hippocampal oxidative DNA damage in young kindled rats. Pharmac Biochem Behav 135:105–113
Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH (1994) Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci 14:5223–5235
Bannai S, Tateishi N (1986) Role of membrane transport in metabolism and function of glutathione in mammals. J Membr Biol 89:1–8
Bradford MM (1976) Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
CINAPS Compound Dossiers (2017) Levetiracetam. National Institute of Neurological Disorders and Stroke, USA
Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Petersen MR, Scheller RH, Chavkin C, Bajjalieh SM (1999) Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). PNAS (USA) 6:15268–15273
de Tommaso M, Di Fruscolo O, Sciruicchio V, Specchio N, Cormio C, De Caro MF, Livrea P (2005) Efficacy of levetiracetam in Huntington disease. Clin Neuropharmacol 28:280–284
Dubovsky SL, Daurignac E, Leonard K, Serotte JC (2001) Levetiracetam, calcium antagonism, and bipolar disorder. Seizure 10:287–293
El-Aal HAHMA (2012) Chapter 3: lipid peroxidation end-products as a key of oxidative stress: effect of antioxidant on their production and transfer of free radicals. In: Catala A (ed) Biochemistry, genetics and molecular biology “lipid peroxidation”. InTechOpen, Rijeka, pp 63–88
Guillemin GJ (2012) Quinolinic acid: the inescapable neurotoxin. FEBS J 279:1356–1365
Hanon E, Klitgaard H (2001) Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure 10:287–293
Harada S, Tanaka S, Takahashi Y, Matsumura H, Shimamoto C, Nakano T, Kuwabara H, Sawabe Y, Nakahari T (2013) Inhibition of Ca(2+)-regulated exocytosis by levetiracetam, a ligand for SV2A, in antral mucous cells of guinea pigs. Eur J Pharmacol 721:185–192
Janz R, Goda Y, Geppert M, Missler M, Südhof TC (1999) SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron 24:1003–1016
Janz R, Südhof TC (1999) SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience 94:1279–1290
Jhamandas KH, Boegman RJ, Beninger RJ, Miranda AE, Lipic KA (2000) Excitotoxicity of quinolinic acid: modulation by endogenous antagonists. Neurotox Res 2:139–155
Lukyanetz EA, Shkryl VM, Kostyuk PG (2002) Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43:9–18
Marini H, Costa C, Passaniti M, Esposito M, Campo GM, Ientile R, Adamo EB, Marini R, Calabresi P, Altavilla D, Minutoli L, Pisani F, Squadrito F (2004) Levetiracetam protects against kainic acid-induced toxicity. Life Sci 74:1253–1264
Martínez-Flórez S, González-Gallego J, Culabras JM, Tuñón MJ (2002) Los flavonoides: propiedades y acciones antioxidantes. Nutr Hosp (Nutrición Hospitalaria), Madrid XVII: 271–278
Mattson MP (2003) Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. NeuroMolecular Med 3:65–94
Mazhar F, Malhi SM, Simjee SU (2017) Comparative studies on the effects of clinically used anticonvulsants on the oxidative stress biomarkers in pentylenetetrazole-induced kindling model of epileptogenesis in mice. J Basic Clin Physiol Pharmacol 28:31–42
Miyazaki I, Murakami S, Torigoe N, Kitamura Y, Asanuma M (2016) Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice. J Neurochem 136:194–204
Oliveira AA, Almeida JP, Freitas RM, Nascimento VS, Aguiar LM, Júnior HV, Fonseca FN, Viana GS, Sousa FC, Fonteles MM (2007) Effects of levetiracetam in lipid peroxidation level, nitrite-nitrate formation and antioxidant enzymatic activity in mice brain after pilocarpine-induced seizures. Cell Mol Neurobiol 27:395–406
Patel SA, Warren BA, Rhoderick JF, Bridges RJ (2004) Differentiation of substrate and non-substrate inhibitors of transport system xc(−): an obligate exchanger of L-glutamate and L-cystine. Neuropharmacology 46:273–284
Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. USA. Academic Press Inc., San Diego
Pérez-De La Cruz V, Carrillo-Mora P, Santamaría A (2012) Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. Int J Tryptophan Res 5:1–8
Pierozan P, Zamoner A, Soska AK, Silvestrin RB, Loureiro SO, Heimfarth L, Mello e Souza T, Wajner M, Pessoa-Pureur R (2010) Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats. Exp Neurol 224:188–196
Pyle RA, Schivell AE, Hidaka H, Bajjalieh SM (2000) Phosphorylation of synaptic vesicle protein 2 modulates binding to synaptotagmin. J Biol Chem 275:17195–17200
Rangel-López E, Colín-González AL, Paz-Loyola AL, Pinzón E, Torres I, Serratos IN, Castellanos P, Wajner M, Souza DO, Santamaría A (2015) Cannabinoid receptor agonists reduce the short-term mitochondrial dysfunction and oxidative stress linked to excitotoxicity in the rat brain. Neuroscience 285:97–106
Schwarcz R, Stone TW (2017) The kynurenine pathway and the brain: challenges, controversies and promises. Neuropharmacology 112:237–247
Silva-Adaya D, Pérez-De La Cruz V, Herrera-Mundo MN, Mendoza-Macedo K, Villeda-Hernández J, Binienda Z, Ali SF, Santamaría A (2008) Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of L-carnitine. J Neurochem 105:677–689
Tavares RG, Tasca CI, Santos CE, Alves LB, Porciúncula LO, Emanuelli T, Souza DO (2002) Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 40:621–627
Tobón-Velasco JC, Silva-Adaya D, Carmona-Aparicio L, García E, Galván-Arzate S, Santamaría A (2010) Early toxic effect of 6-hydroxydopamine on extracellular concentrations of neurotransmitters in the rat striatum: an in vivo microdialysis study. Neurotoxicology 31:715–723
Ueda Y, Doi T, Takaki M, Nagatomo K, Nakajima A, Willmore LJ (2009) Levetiracetam enhances endogenous antioxidant in the hippocampus of rats: in vivo evaluation by brain microdialysis combined with ESR spectroscopy. Brain Res 1266:1–7
Wang H, Gao J, Lassiter TF, McDonagh DL, Sheng H, Warner DS, Lynch JR, Laskowitz DT (2006) Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit Care 5:71–78
Winden KD, Karsten SL, Bragin A, Kudo LC, Gehman L, Ruidera J, Geschwind DH, Engel J Jr (2011) A systems level, functional genomics analysis of chronic epilepsy. PLoS One 6:e20763
The experimental protocols were approved by the Ethics Committee of the INNN.
Conflict of Interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Dircio-Bautista, M., Colín-González, A.L., Aguilera, G. et al. The Antiepileptic Drug Levetiracetam Protects Against Quinolinic Acid-Induced Toxicity in the Rat Striatum. Neurotox Res 33, 837–845 (2018). https://doi.org/10.1007/s12640-017-9836-4
- Neurotransmitter release
- Oxidative damage
- Motor alterations
- Brain tissue damage
- Antiepileptic drug